BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants chronically infected with Hepatitis C virus (HCV) genotype 1
HCV RNA viral load of ≥10,000 IU/mL at screening
No previous exposure to interferon formulation, ribavirin or HCV direct antiviral agent
Self-described as Black-African American, Latino or White-Caucasian
Results of a liver biopsy obtained ≤36 months prior to first treatment compensated cirrhotics with HCV liver biopsy from any time prior to first treatment.
Compensated cirrhotics were capped at approximately 25%
You may not be if
Evidence of decompensated liver disease
Documented or suspected Hepatocellular carcinoma (HCC)
Positive for Hepatitis B or HIV 1/HIV 2 antibody at screening
Clareo Health | BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
